CSL Behring LLC
1020 FIRST AVENUE KING OF PRUSSIA, PA 19406-0901 USA |
Lobbying on the following issues:
HEALTH ISSUES H.R. 3/S. 2543--Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act; Administration Advance Notice of Proposed Rulemaking on International Pricing Index; International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. H.R. 2296--METRIC Act--Drug Price transparency reporting requirements - Lobbyists: COLLINS, PATRICKGRANT, JULIA
|
Lobbying on the following issues:
HEALTH ISSUES H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity - Lobbyists: COLLINS, PATRICKGRANT, JULIA
Foreign Entities: Foreign Entity Name: Interel, SA/NVCountry : BELGIUMContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response. - Lobbyists: COLLINS, PATRICKGRANT, JULIA
Foreign Entities: Foreign Entity Name: Volvo Bus CorporationCountry : SWEDENContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES GOVERNMENT ISSUES TAXATION/INTERNAL REVENUE CODE Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index HHS Proposed Rule Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees - H.R. 1--For the People Act of 2019--US lobbying registration requirements for international companies - Preserving Access to Orphan Drugs Act--Orphan Drugs Exclusion from the Branded Annual Pharmaceutical Fee - Lobbyists: JACKMAN, DENNISCOLLINS, PATRICKGRANT, JULIA
Foreign Entities: Foreign Entity Name: Bavarian Nordic A/SCountry : DENMARKContribution : $200,000 |
Lobbying on the following issues:
GOVERNMENT ISSUES TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES Multiple proposals to strengthen Foreign Agents Registration Act, including S. 2039/HR 4170, Disclosing Foreign Influence Act--US Lobbying registration requirements for international companies - H.R. 7324--Preserving Access to Orphan Drugs Act--Orphan Drugs Exclusion from the Branded Annual Pharmaceutical Fee - H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act - Lobbyists: JACKMAN, DENNISCOLLINS, PATRICKGRANT, JULIA
|
Lobbying on the following issues:
GOVERNMENT ISSUES HEALTH ISSUES H.R. 1--For the People Act of 2019--US lobbying registration requirements for international companies - HR 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index S. 474 (Senate SPIKE Act), HR 2113 (House STAR Act), HR 2296 (House FAIR Act)--Drug Pricing Transparency reporting requirements Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self-administered drug lists by Medicare contractors. - Lobbyists: JACKMAN, DENNISCOLLINS, PATRICKGRANT, JULIA
Foreign Entities: Foreign Entity Name : Philip Morris Brands Sarl (Parent company is PMI)Country : SWITZERLANDContribution : $0 - Foreign Entity Name : Philip Morris Products S.A. (Parent company is PMI)Country : SWITZERLANDContribution : $0 - Foreign Entity Name : PMI Management, SA (Parent Co. is PMI)Country : |
Money Spent:
Amount | Client | Government Entities |
---|
$330,000
Oct 21, 2019
THIRD QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE
$280,000
Jan 21, 2020
FOURTH QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE
$200,000
Apr 20, 2020
FIRST QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE
$190,000
Apr 22, 2019
FIRST QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE
$140,000
Jan 22, 2019
FOURTH QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE
$110,000
Jul 22, 2019
SECOND QUARTER REPORT
CSL BEHRING LLC
HOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)SENATE